Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Glucagon-like peptide 1 (GLP-1) receptor agonists use during pregnancy: safety data from regulatory clinical trials
This guide provides evidence-based recommendations to minimize nausea while maintaining the therapeutic benefits of GLP-1 therapy
doi: 10.2337/dc23-1287 91 JiLJiangHBiYLiHTianJLiuDet al
On the other hand, Structure Therapeutics, Viking Therapeutics, AstraZeneca and Merck & Co., Inc
Conversely, venglustat, a glucosylceramide synthase inhibitor, failed to show any clinical benefit over placebo in GBA1-related PD in part 2 of a recent phase 2 trial [126], after having demonstrated favourable safety, tolerability, and target engagement in the cerebrospinal fluid (CSF) in part 1 of the same trial [127]
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
